StockData
Merck & Co., Inc. logo

Merck & Co., Inc.

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30250% above fair value
$148.36−1.16 (-0.78%)

Close on Nov 2, 2026Market cap $366.03BP/E 118.7Yield 2.21%

Merck 2024 Restructuring Program by Year

2024 Restructuring Program (Supply Network & Commercial Optimization) — Ending Accrual Reserve Balance ($M) ($M)

Merck 2024 Restructuring Program: $506M in FY2025, down 10.3% from a year earlier.

Latest, FY2025
506
Period ended Dec 31, 2025
Change on a year earlier
-10.3%
564 in FY2024
History
4 years
Since FY2022
Sources
3
Documents cited below

Where the FY2025 figure comes from

Source: Form 10-Q (filed 2026-08-07) ↗

Reported in Form 10-Q / 10-K Restructuring Footnote.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEnded2024 Restructuring Program (Supply Network & Commercial Optimization) — Ending Accrual Reserve Balance ($M) ($M)Year on yearSource
FY2025Dec 31, 2025506-10.3%Form 10-Q (filed 2026-08-07) ↗
FY2024Dec 31, 2024564-20.8%Form 10-K (filed 2026-02-24) ↗
FY2023Dec 31, 2023712–Form 10-K (filed 2026-02-24) ↗
FY2022Dec 31, 20220–Form 10-K (filed 2024-02-26) ↗

Cite this data

StockData. (2026). Merck 2024 Restructuring Program ($M), annual FY2022–FY2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/restr-program2024-res-tot

See every metric in the Merck KPI table. Data updated Oct 26, 2026.